F. Friedrich

发表

Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue

L. Carrier, T. Eschenhagen, Alexander Dutsch, 2019, Scientific Reports.

Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue

K. Lorenz, M. Schweizer, I. Wittig, 2021, Redox biology.

FHL2 expression and variants in hypertrophic cardiomyopathy

C. Hengstenberg, W. Linke, O. Müller, 2014, Basic Research in Cardiology.

COPD Exacerbation History and Impact on Future Exacerbations – 8-Year Retrospective Observational Database Cohort Study from Germany

C. Vogelmeier, F. Friedrich, M. Pignot, 2021, International journal of chronic obstructive pulmonary disease.

Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model

L. Carrier, F. Friedrich, S. Stücker, 2017, Front. Physiol..

The E3 ubiquitin ligase Asb2β is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation.

H. Schlüter, L. Carrier, T. Eschenhagen, 2015, Journal of molecular and cellular cardiology.

Diltiazem prevents stress‐induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3‐knock‐in mice

F. Weinberger, L. Carrier, T. Eschenhagen, 2017, The Journal of physiology.

Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy.

L. Maier, S. Wagner, E. Schwedhelm, 2016, Cardiovascular research.

Distinction between two populations of islet-1-positive cells in hearts of different murine strains.

M. Fiszman, K. Schwartz, L. Carrier, 2011, Stem cells and development.

S100A4 as a Target of the E3-Ligase Asb2β and Its Effect on Engineered Heart Tissue

J. Gross, Shirin Doroudgar, L. Carrier, 2018, Front. Physiol..

Localization of Islet-1–Positive Cells in the Healthy and Infarcted Adult Murine Heart

F. Weinberger, L. Carrier, T. Eschenhagen, 2012, Circulation research.

Disease modeling of a mutation in α‐actinin 2 guides clinical therapy in hypertrophic cardiomyopathy

Jussi T. Koivumäki, D. Catalucci, M. Spohn, 2019, EMBO molecular medicine.

Analysis of Contractile Function of Permeabilized Human Hypertrophic Cardiomyopathy Multicellular Heart Tissue

L. Carrier, C. Redwood, F. Friedrich, 2019, Front. Physiol..

Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.

L. Carrier, A. Eder, T. Eschenhagen, 2016, Journal of molecular and cellular cardiology.

Automated analysis of contractile force and Ca2+ transients in engineered heart tissue.

Thomas Eschenhagen, Arne Hansen, Alexandra Eder, 2014, American journal of physiology. Heart and circulatory physiology.

Ouabain worsens diastolic sarcomere length in myocytes from a cardiomyopathy mouse model.

M. Kohlhaas, C. Maack, L. Carrier, 2021, European journal of pharmacology.

Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial

S. Blankenberg, F. Friedrich, S. Sehner, 2018, Journal of cardiovascular pharmacology and therapeutics.

A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy.

E. Arbustini, M. Komajda, K. Wegscheider, 2009, European heart journal.

Genetics of hypertrophic and dilated cardiomyopathy.

L. Carrier, F. Friedrich, 2012, Current pharmaceutical biotechnology.

Control of bone formation by the serpentine receptor Frizzled-9

G. Sauter, K. Knobeloch, U. Francke, 2011, The Journal of cell biology.

Negative Regulation of Bone Formation by the Transmembrane Wnt Antagonist Kremen-2

R. Baron, C. Niehrs, A. Schilling, 2010, PloS one.

COPD_A_252354 1335..1347

F. Friedrich, J. Beier, 2020 .

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study

F. Friedrich, J. Beier, T. Plate, 2019, Pneumologie.

Effect of ranolazine on plasma arginine derivatives and urinary isoprostane 8-iso-PGF2α in patients with myocardial infarction in the randomized RIMINI-Trial

S. Blankenberg, E. Schwedhelm, R. Böger, 2019, Scientific Reports.

Epigallocatechin-3-Gallate Accelerates Relaxation and Ca2+ Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice

L. Carrier, T. Eschenhagen, F. Friedrich, 2016, Front. Physiol..

Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy.

Eloisa Arbustini, Christian Hengstenberg, Philippe Charron, 2012, Human molecular genetics.

Current treatment landscape of pancreatic cancer patients in a network of office-based oncologists in Germany.

K. Kratz-Albers, F. Friedrich, S. Hegewisch‐Becker, 2022, Future oncology.

Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.

Thomas Eschenhagen, Arne Hansen, Alexandra Eder, 2013, Journal of molecular and cellular cardiology.

I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model

L. Carrier, T. Eschenhagen, F. Friedrich, 2015, International journal of cardiology. Heart & vasculature.

A novel genetic variant in the transcription factor Islet‐1 exerts gain of function on myocyte enhancer factor 2C promoter activity

M. Komajda, L. Gouya, P. Charron, 2013, European journal of heart failure.